MX2022016212A - Profármacos de tripamina. - Google Patents
Profármacos de tripamina.Info
- Publication number
- MX2022016212A MX2022016212A MX2022016212A MX2022016212A MX2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A
- Authority
- MX
- Mexico
- Prior art keywords
- tryptamine
- prodrugs
- zwitterions
- depression
- symbol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045901P | 2020-06-30 | 2020-06-30 | |
| US202063109095P | 2020-11-03 | 2020-11-03 | |
| PCT/CA2021/050907 WO2022000091A1 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
| US17/364,047 US11292765B2 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016212A true MX2022016212A (es) | 2023-03-02 |
Family
ID=79032374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016212A MX2022016212A (es) | 2020-06-30 | 2021-06-30 | Profármacos de tripamina. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11292765B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4172145B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7702654B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102829078B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN119285527A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021302692A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181092A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4172145T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4172145T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL299506B2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT4172145T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016212A (cg-RX-API-DMAC7.html) |
| PT (1) | PT4172145T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022000091A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| AU2021215709A1 (en) | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| DK4172145T3 (da) * | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| WO2022040802A1 (en) * | 2020-08-26 | 2022-03-03 | Magicmed Industries Inc. | Glycosylated psilocybin derivatives and methods of using |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| JP2024520832A (ja) | 2021-06-08 | 2024-05-24 | エンセオジェニックス バイオサイエンシズ, インコーポレイテッド | セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤 |
| AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| KR20240065084A (ko) * | 2021-08-20 | 2024-05-14 | 테란 바이오사이언시스 인코포레이티드 | 사일로신의 전구약물 및 유도체 및 그의 용도 |
| WO2023086962A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| AU2022408191B2 (en) * | 2021-12-10 | 2025-05-15 | Caamtech, Inc. | Psilocybin derivatives |
| US20250051278A1 (en) * | 2021-12-14 | 2025-02-13 | Reunion Neuroscience, Inc. | Tryptamine prodrugs |
| CA3242479A1 (en) | 2021-12-27 | 2023-07-06 | Atai Therapeutics, Inc. | AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| US20250066299A1 (en) * | 2022-01-06 | 2025-02-27 | Terran Biosciences Inc. | Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20250186369A1 (en) * | 2022-03-07 | 2025-06-12 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder |
| AU2023235712A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| US12065404B2 (en) * | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493541A4 (en) * | 2022-03-18 | 2026-02-25 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBOXYLIC ACID AND METHODS OF USE |
| AU2022447256A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-carbonothioate-substituted tryptamine derivatives and methods of using |
| AU2023254841B2 (en) * | 2022-04-13 | 2025-10-23 | Caamtech, Inc. | Tryptamine derivatives |
| CN115521240B (zh) * | 2022-06-01 | 2024-05-28 | 杭州奥泰生物技术股份有限公司 | 一种二甲基色胺半抗原和人工抗原及其制备方法与应用 |
| AU2023313326A1 (en) * | 2022-07-27 | 2024-12-19 | Reconnect Labs Ag | Highly soluble formulations of harmine |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN116283885B (zh) * | 2022-12-01 | 2025-02-14 | 杭州奥泰生物技术股份有限公司 | 一种帕罗西汀半抗原和人工抗原及其制备方法与应用 |
| WO2024145719A1 (en) * | 2023-01-05 | 2024-07-11 | Reunion Neuroscience Inc. | Improved pharmacokinetics of tryptamine prodrugs |
| WO2024178051A2 (en) * | 2023-02-22 | 2024-08-29 | Caamtech, Inc. | Tryptamine derivatives |
| US12343319B2 (en) | 2023-05-01 | 2025-07-01 | Atai Therapeutics, Inc. | Compositions and methods for treatment of diseases and disorders |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025099725A1 (en) * | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2025250900A1 (en) * | 2024-05-30 | 2025-12-04 | Caamtech, Inc. | 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
| WO2026128398A1 (en) * | 2024-12-09 | 2026-06-18 | Reunion Neuroscience, Inc. | Treatment of adjustment disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| NL121067C (cg-RX-API-DMAC7.html) | 1958-09-12 | |||
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| WO1995006638A1 (en) * | 1993-09-01 | 1995-03-09 | Allelix Biopharmaceuticals Inc. | Tryptamine analogs with 5-ht1d selectivity |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2006047032A2 (en) | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| US8809261B2 (en) | 2008-10-31 | 2014-08-19 | Elsohly Laboratories, Incorporated | Compositions containing delta-9-THC-amino acid esters and process of preparation |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| DK4172145T3 (da) * | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
-
2021
- 2021-06-30 DK DK21832431.7T patent/DK4172145T3/da active
- 2021-06-30 CN CN202410898937.9A patent/CN119285527A/zh active Pending
- 2021-06-30 CA CA3181092A patent/CA3181092A1/en active Pending
- 2021-06-30 WO PCT/CA2021/050907 patent/WO2022000091A1/en not_active Ceased
- 2021-06-30 EP EP21832431.7A patent/EP4172145B1/en active Active
- 2021-06-30 AU AU2021302692A patent/AU2021302692A1/en active Pending
- 2021-06-30 FI FIEP21832431.7T patent/FI4172145T3/fi active
- 2021-06-30 KR KR1020237003292A patent/KR102829078B1/ko active Active
- 2021-06-30 KR KR1020257021837A patent/KR20250103811A/ko active Pending
- 2021-06-30 EP EP26177764.3A patent/EP4786000A2/en active Pending
- 2021-06-30 US US17/364,047 patent/US11292765B2/en active Active
- 2021-06-30 LT LTEPPCT/CA2021/050907T patent/LT4172145T/lt unknown
- 2021-06-30 CN CN202410898893.XA patent/CN119285526A/zh active Pending
- 2021-06-30 PT PT218324317T patent/PT4172145T/pt unknown
- 2021-06-30 JP JP2022580938A patent/JP7702654B2/ja active Active
- 2021-06-30 CN CN202180046999.1A patent/CN115867533B/zh active Active
- 2021-06-30 IL IL299506A patent/IL299506B2/en unknown
- 2021-06-30 MX MX2022016212A patent/MX2022016212A/es unknown
-
2022
- 2022-02-24 US US17/679,439 patent/US20220177427A1/en not_active Abandoned
-
2024
- 2024-09-30 US US18/902,773 patent/US20250129023A1/en active Pending
-
2025
- 2025-04-30 IL IL320601A patent/IL320601A/en unknown
- 2025-06-05 JP JP2025094025A patent/JP7864902B2/ja active Active
- 2025-08-22 US US19/308,120 patent/US20250382267A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102829078B1 (ko) | 2025-07-04 |
| IL320601A (en) | 2025-07-01 |
| CN115867533B (zh) | 2024-07-23 |
| EP4172145A1 (en) | 2023-05-03 |
| US20210403425A1 (en) | 2021-12-30 |
| IL299506B2 (en) | 2025-10-01 |
| JP7702654B2 (ja) | 2025-07-04 |
| IL299506A (en) | 2023-02-01 |
| IL299506B1 (en) | 2025-06-01 |
| EP4172145A4 (en) | 2024-08-21 |
| LT4172145T (lt) | 2026-07-27 |
| US20250129023A1 (en) | 2025-04-24 |
| CN115867533A (zh) | 2023-03-28 |
| KR20230028543A (ko) | 2023-02-28 |
| JP7864902B2 (ja) | 2026-05-25 |
| CN119285527A (zh) | 2025-01-10 |
| DK4172145T3 (da) | 2026-07-20 |
| US11292765B2 (en) | 2022-04-05 |
| EP4786000A2 (en) | 2026-08-05 |
| KR20250103811A (ko) | 2025-07-07 |
| FI4172145T3 (fi) | 2026-07-22 |
| JP2023531311A (ja) | 2023-07-21 |
| AU2021302692A1 (en) | 2023-01-19 |
| EP4172145B1 (en) | 2026-05-13 |
| PT4172145T (pt) | 2026-07-17 |
| US20250382267A1 (en) | 2025-12-18 |
| CN119285526A (zh) | 2025-01-10 |
| CA3181092A1 (en) | 2022-01-06 |
| WO2022000091A1 (en) | 2022-01-06 |
| US20220177427A1 (en) | 2022-06-09 |
| JP2025143280A (ja) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021011188A2 (es) | Compuesto heterocíclico y su uso | |
| CO2020001879A2 (es) | Compuesto heterocíclico y su uso | |
| CO2018008705A2 (es) | Compuestos de piperidina sustituido y su uso | |
| MX2023000693A (es) | Inhibidor de egfr. | |
| ECSP13012478A (es) | Compuesto heterocíclico y su uso | |
| MX2013009957A (es) | Agente de control de endoparasitos. | |
| CO2025005865A2 (es) | Compuesto heterocíclico | |
| CR10564A (es) | Compuestos cíclicos fusionados | |
| MX2017016413A (es) | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. | |
| CO6491037A2 (es) | Derivados de pirazinooxazepina | |
| CO6260091A2 (es) | Derivados de iminopiridina y su uso | |
| UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CL2025001563A1 (es) | Compuesto heterocíclico y uso del mismo | |
| CO2022010011A2 (es) | Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo | |
| MX2019002314A (es) | Compuesto de 1-acetil-fenil urea, y uso del mismo. | |
| PE20191788A1 (es) | Compuesto de n-(4-piridil)nicotinamida o sal del mismo | |
| AR109406A1 (es) | Compuesto de 1-fenil-3-carbamoilurea y su uso | |
| ECSP23088732A (es) | Moduladores de trex1 | |
| MX2019010967A (es) | Agente terapeutico o profilactico para neuropatias perifericas. | |
| CO2025012357A2 (es) | Compuestos heterocíclicos macrocíclicos y sus usos | |
| AR132690A1 (es) | Antagonista del receptor de melanocortina 2 | |
| CO2019012270A2 (es) | Compuesto heterocíclico | |
| AR109405A1 (es) | Compuestos de fenilurea y su uso | |
| CO2024007757A2 (es) | Sistema generador de aerosol | |
| AR109408A1 (es) | Compuesto de 3-piridiloxianilina y su uso |